<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-60879" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Irinotecan</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reyhanoglu</surname>
            <given-names>Gizem</given-names>
          </name>
          <aff>LECOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Travis</given-names>
          </name>
          <aff>LECOM at Jacksonville University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gizem Reyhanoglu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Travis Smith declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-60879.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Irinotecan is a medication used to manage and treat a variety of solid tumors. It is in the DNA topoisomerase I inhibitor class of drugs. Also known as CPT-11, irinotecan is used adjunctively with other therapeutic agents against colorectal cancer as a first- or second-line treatment. This activity reviews the indications, action, and contraindications for irinotecan as a valuable agent in treating solid tumors such as colorectal, pancreatic, ovarian, and lung cancers. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for healthcare team members in the care of patients who receive treatment with this medication.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of irinotecan.</p></list-item><list-item><p>Describe the adverse effects associated with irinotecan.</p></list-item><list-item><p>Review the appropriate monitoring for Irinotecan.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to ensure the optimal therapeutic results with irinotecan resulting in optimal patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=60879&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=60879">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-60879.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Irinotecan is a DNA topoisomerase I inhibitor that received approval for use in the United States in 1996.<xref ref-type="bibr" rid="article-60879.r1">[1]</xref>&#x000a0;It is derived from the Chinese tree, <italic toggle="yes">Camptotheca acuminate,</italic>&#x000a0;and is used as a chemotherapy agent against various solid tumors, such as colorectal, pancreatic, ovarian, and lung cancers.<xref ref-type="bibr" rid="article-60879.r2">[2]</xref>&#x000a0;Also known as CPT-11, irinotecan is used adjunctively with other therapeutic agents against colorectal cancer as a first- or second-line treatment.<xref ref-type="bibr" rid="article-60879.r3">[3]</xref></p>
        <p>
<bold>FDA-approved Uses</bold>
</p>
        <p>
<bold>Colorectal Cancer</bold>
</p>
        <p>Colorectal cancer is the third most common cause of cancer mortality in the United States.&#x000a0;It constitutes about 10% of worldwide cancer deaths.<xref ref-type="bibr" rid="article-60879.r4">[4]</xref>&#x000a0;Irinotecan is combined with 5-fluorouracil (5-FU) and leucovorin for maximum efficacy against colorectal cancer.<xref ref-type="bibr" rid="article-60879.r3">[3]</xref>&#x000a0;It is considered more efficacious in combination with 5-FU/leucovorin than the separate individual use of the agents. This combination is also known as the FOLFIRI regimen.<xref ref-type="bibr" rid="article-60879.r5">[5]</xref>&#x000a0;With therapy regimens like FOLFIRI, the median survival rate of a patient with metastatic colorectal cancer has improved from 8 months to 24 months.<xref ref-type="bibr" rid="article-60879.r4">[4]</xref></p>
        <p>Capecitabine, the pro-drug of 5-FU, is also combined with irinotecan for a treatment regimen known as XELIRI.&#x000a0;There is insufficient supporting evidence to state whether FOLFIRI or XELIRI works better against colorectal cancer.<xref ref-type="bibr" rid="article-60879.r6">[6]</xref>&#x000a0;Both are considered first-line therapy, and both share similar side effect profiles.&#x000a0;</p>
        <p>Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), is combined with irinotecan for patients with wild-type K-Ras colorectal tumors.<xref ref-type="bibr" rid="article-60879.r7">[7]</xref></p>
        <p>
<bold>Pancreatic Cancer</bold>
</p>
        <p>Pancreatic ductal adenocarcinoma has a poor prognosis due to its late stage of presentation, increased susceptibility to metastasizing, and resistance to treatments.&#x000a0;Nanoliposomal irinotecan, combined with 5-FU/leucovorin, was approved for the treatment of pancreatic cancer in October 2015.&#x000a0;Nanoliposomal irinotecan allows for better pharmacokinetics and biodistribution due to the drug's encapsulation within liposome-based nanoparticles. Because of how aggressive pancreatic cancer is and how recently the approval of this regimen is, there is no set sequencing of therapy to be considered superior. It is up to the provider and the patient's age and status.<xref ref-type="bibr" rid="article-60879.r8">[8]</xref></p>
        <p>
<bold>Non-FDA-approved Uses</bold>
</p>
        <p>
<bold>Ovarian Cancer</bold>
</p>
        <p>Ovarian cancer is the second most common gynecologic malignancy in the United States. To treat ovarian cancer, irinotecan is combined with cisplatin, a platinum analog that cross-links DNA.&#x000a0;It is still undergoing clinical trials, but early phase I and phase II trials show response rates of 20% to 25% in patients with recurrent or refractory disease.<xref ref-type="bibr" rid="article-60879.r9">[9]</xref>&#x000a0;</p>
        <p>
<bold>Lung Cancer</bold>
</p>
        <p>The current chemotherapy regimen for small-cell lung cancer is etoposide and cisplatin.&#x000a0;Recent studies&#x000a0;have been demonstrating the efficacy of irinotecan with cisplatin.&#x000a0;Myelosuppression is the most common side effect with either regimen researchers note it to be worse in patients receiving etoposide and cisplatin. Using irinotecan in place of etoposide, a topoisomerase II inhibitor could allow patients to tolerate the regimen longer and thus improve outcomes.<xref ref-type="bibr" rid="article-60879.r10">[10]</xref></p>
      </sec>
      <sec id="article-60879.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>DNA topoisomerase I is involved in the relaxation of the DNA double helix during replication and transcription.<xref ref-type="bibr" rid="article-60879.r11">[11]</xref> The enzyme does this by creating single-strand breaks in the DNA, relieving the DNA of supercoiling.<xref ref-type="bibr" rid="article-60879.r11">[11]</xref></p>
        <p>Irinotecan is a prodrug that inhibits DNA topoisomerase I, acting on the S and G2 phases of the cell cycle.<xref ref-type="bibr" rid="article-60879.r2">[2]</xref> Irinotecan becomes activated to its biologically active metabolite, SN-38, through the actions of hydrolysis&#x000a0;by a carboxylesterase to form its active metabolite SN-38.<xref ref-type="bibr" rid="article-60879.r12">[12]</xref> The activity of UDP-glucuronyltransferases inactivates SN-38 to its SN-38G form.<xref ref-type="bibr" rid="article-60879.r13">[13]</xref></p>
      </sec>
      <sec id="article-60879.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Irinotecan is a hydrophilic compound with a large volume of distribution.<xref ref-type="bibr" rid="article-60879.r2">[2]</xref> Treatment with irinotecan can be&#x000a0;via 30- or 90-minute intravenous infusions of 125 mg/m^2 weekly for 4 of every six weeks or 350 mg/m^2 every three weeks.<xref ref-type="bibr" rid="article-60879.r1">[1]</xref> After comparative clinical trials of irinotecan administration, researchers noted no superior administration method exists.<xref ref-type="bibr" rid="article-60879.r1">[1]</xref>&#x000a0;Prolonged infusions demonstrated improvement with irinotecan's side effect profile.<xref ref-type="bibr" rid="article-60879.r3">[3]</xref></p>
      </sec>
      <sec id="article-60879.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of irinotecan are primarily due to its active metabolite, SN-38. Common adverse effects include neutropenia, diarrhea, nausea, vomiting, alopecia, and fatigue.<xref ref-type="bibr" rid="article-60879.r1">[1]</xref> Neutropenia associated with irinotecan is usually short-lived but can be severe if diarrhea is also present.<xref ref-type="bibr" rid="article-60879.r14">[14]</xref> If patients have the&#x000a0;UGT1A1*28 allele of the UDP-glucuronosyltransferase&#x000a0;enzyme that inactivates SN-38 into the SN-38G form, there is decreased glucuronidation into the SN-38G form.&#x000a0;The UGT1A1*28 allele is associated with increased diarrhea events of neutropenia because the active form, SN-38, cannot be inactivated as effectively.<xref ref-type="bibr" rid="article-60879.r15">[15]</xref></p>
        <p>New regimens and administration schedules are under investigation to reduce the adverse effects that cause limitations on irinotecan use.<xref ref-type="bibr" rid="article-60879.r16">[16]</xref> Atropine sulfate has been administered with irinotecan to minimize the amount of irinotecan-induced diarrhea in patients.<xref ref-type="bibr" rid="article-60879.r7">[7]</xref> Loperamide administration with irinotecan has also been an effective medication to treat diarrhea.<xref ref-type="bibr" rid="article-60879.r11">[11]</xref></p>
      </sec>
      <sec id="article-60879.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to irinotecan would involve severe allergic reactions to its group of chemotherapeutic agents, the DNA topoisomerase I inhibitors. Irinotecan is contraindicated in gastric cancer patients with peritoneal metastasis or impaired liver function.&#x000a0;If this is the case, paclitaxel is a better alternative to consider.<xref ref-type="bibr" rid="article-60879.r17">[17]</xref>&#x000a0;Pregnancy and lactation are contraindications, as irinotecan has shown embryotoxic and teratogenic effects. Administration of CYP3A4 inhibitor agents should be avoided to decrease the likelihood of increased toxicity.</p>
      </sec>
      <sec id="article-60879.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The active metabolite of irinotecan, SN-38, is about 100 to 1000-fold more cytotoxic than irinotecan. SN-38 is inactivated by enzymatic conversion through UDP-glucuronosyltransferase into SN-38G.<xref ref-type="bibr" rid="article-60879.r2">[2]</xref> The cytochrome P450 isoenzyme 3A4 can also metabolize irinotecan into an inactive form known as APC.<xref ref-type="bibr" rid="article-60879.r11">[11]</xref> Irinotecan and its metabolites are eliminated through the liver; therefore, patients with liver dysfunction should be monitored carefully for possible toxicities when using this chemotherapy agent.<xref ref-type="bibr" rid="article-60879.r1">[1]</xref></p>
        <p>The monitoring of appropriate concentrations of irinotecan for patients is through total bilirubin levels.<xref ref-type="bibr" rid="article-60879.r18">[18]</xref> Dosing can appropriately be determined for patients using this metric, especially those with liver dysfunction. The half-life of irinotecan averages to be about 10 hours.<xref ref-type="bibr" rid="article-60879.r11">[11]</xref> Acquired resistance to irinotecan or its active metabolite, SN-38, is one of the main obstacles to treatment for advanced colorectal cancer.<xref ref-type="bibr" rid="article-60879.r4">[4]</xref></p>
      </sec>
      <sec id="article-60879.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Life-threatening toxicities can occur even in patients who are in relatively good conditions. When a patient is unable to manage the side effect profile of irinotecan, it limits the therapeutic advantages that come with its use. Most of the irinotecan's side effect profile is due to its active metabolite, SN-38. Researchers have noted higher incidences of toxicity with genetic polymorphisms to the UDP-glucuronosyltransferase 1A1 gene. A particular polymorphism, UDP1A1*28, decreases the inactivation of SN-38, causing adverse toxic effects.<xref ref-type="bibr" rid="article-60879.r16">[16]</xref>&#x000a0;Patients with Gilbert disease, a syndrome of mildly decreased levels of UDP-glucuronyltransferase provoked at times of stress, suffer toxic side effects more commonly than patients not diagnosed with Gilbert disease.<xref ref-type="bibr" rid="article-60879.r5">[5]</xref>&#x000a0;</p>
        <p>Among the most common dose-limiting toxicities of irinotecan, commonly shared with the DNA topoisomerase I inhibitor group of chemotherapeutic agents, is diarrhea. Diarrhea is most widely noted within&#x000a0;7 to 10 days after treatment and can be life-threatening. High-dose loperamide, a dopamine agonist that does not cross the blood-brain barrier, is effective against diarrhea caused by irinotecan. It allows the ability to increase doses during chemotherapy to levels that patients can tolerate.<xref ref-type="bibr" rid="article-60879.r11">[11]</xref></p>
      </sec>
      <sec id="article-60879.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The use of irinotecan for FDA-approved purposes such as colorectal and pancreatic carcinoma has greatly improved patient longevity. Factors that limit its usage mainly&#x000a0;involve dose-limiting toxicities. Irinotecan's appropriate dosing regimen is still unclear, but the medical community has&#x000a0;come to a consensus. The&#x000a0;goal for the recommended dosing of irinotecan involves&#x000a0;limiting&#x000a0;side effects but still providing adequate treatment. The use of irinotecan requires the efforts of an interprofessional healthcare team to be maximally effective.</p>
        <p>To&#x000a0;minimize its&#x000a0;side effects, there have been attempts to manage drug-limiting diarrhea that can occur in patients. A combination&#x000a0;of atropine with irinotecan or loperamide with irinotecan has demonstrated effectiveness in preventing diarrhea in some patients.<xref ref-type="bibr" rid="article-60879.r7">[7]</xref><xref ref-type="bibr" rid="article-60879.r11">[11]</xref>&#x000a0;The medical community&#x000a0;should continue to put in efforts to make irinotecan more tolerable during treatments.</p>
        <p>Irinotecan therapy requires the focused efforts of an interprofessional healthcare team. Board-certified oncologic pharmacists review dosing, check for interactions and assist with patient education, as well as consult with the oncologist or other ordering clinicians. Oncology nurses administer the medication, monitor for side effects, facilitate communication with the team, and chart their observations for use in making therapeutic decisions in the future. These are but two examples of interprofessional teamwork that can improve patient outcomes; this needs to be the norm in healthcare delivery. [Level 5]&#x000a0;</p>
        <p>In a study completed at the Gustave Roussy Institute in 2002, the Department of Medicine conducted a study to determine the appropriate dosing of irinotecan in patients with cancer with hyperbilirubinemia. Researchers noted that the dose-limiting toxicities observed in the patients were mainly neutropenia and diarrhea. Patients with high bilirubin and alkaline phosphatase levels had a&#x000a0;reduction in the clearance of irinotecan.<xref ref-type="bibr" rid="article-60879.r18">[18]</xref>&#x000a0;As healthcare professionals, it is essential to factor in a patient's hepatobiliary function. Since irinotecan and its metabolites are eliminated mainly through the liver, future treatments for patients should be adjusted to decrease accidental hyperbilirubinemia. [Level 5]</p>
        <p>Research has noted that irinotecan works better as a combination therapy. Two main combinations, XELIRI and FOLFIRI, are used to treat colorectal carcinoma. XELIRI is the combination of capecitabine with irinotecan, whereas FOLFIRI is the combination of 5-fluorouracil, leucovorin, and irinotecan. A meta-analysis in 2014 in China demonstrated that one was not superior to the other.<xref ref-type="bibr" rid="article-60879.r6">[6]</xref>&#x000a0;This data is useful for physicians and other healthcare providers in finding the most appropriate and best-suited chemotherapy regimen for their patients. Instead of choosing one over superiority, a healthcare provider can select by reasoning with patient status, tolerability, and age. [Level 5]</p>
      </sec>
      <sec id="article-60879.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=60879&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=60879">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/60879/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=60879">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-60879.s11">
        <title>References</title>
        <ref id="article-60879.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.</article-title>
            <source>World J Gastroenterol</source>
            <year>2015</year>
            <month>Nov</month>
            <day>21</day>
            <volume>21</volume>
            <issue>43</issue>
            <fpage>12234</fpage>
            <page-range>12234-48</page-range>
            <pub-id pub-id-type="pmid">26604633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Man</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Goey</surname>
                <given-names>AKL</given-names>
              </name>
              <name>
                <surname>van Schaik</surname>
                <given-names>RHN</given-names>
              </name>
              <name>
                <surname>Mathijssen</surname>
                <given-names>RHJ</given-names>
              </name>
              <name>
                <surname>Bins</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>57</volume>
            <issue>10</issue>
            <fpage>1229</fpage>
            <page-range>1229-1254</page-range>
            <pub-id pub-id-type="pmid">29520731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Paolo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bocci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Danesi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Del Tacca</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.</article-title>
            <source>Curr Clin Pharmacol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-23</page-range>
            <pub-id pub-id-type="pmid">18666754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makondi</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>e0180616</fpage>
            <pub-id pub-id-type="pmid">28749961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emami</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Sadighi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shirkoohi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mohagheghi</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Prediction of Response to Irinotecan and Drug Toxicity Based on Pharmacogenomics Test: A Prospective Case Study in Advanced Colorectal Cancer.</article-title>
            <source>Asian Pac J Cancer Prev</source>
            <year>2017</year>
            <month>Oct</month>
            <day>26</day>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>2803</fpage>
            <page-range>2803-2807</page-range>
            <pub-id pub-id-type="pmid">29072417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.</article-title>
            <source>Clin Colorectal Cancer</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>110</fpage>
            <page-range>110-8</page-range>
            <pub-id pub-id-type="pmid">24461997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurniali</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hrinczenko</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Al-Janadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of locally advanced and metastatic colon cancer in elderly patients.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Feb</month>
            <day>28</day>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>1910</fpage>
            <page-range>1910-22</page-range>
            <pub-id pub-id-type="pmid">24616568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glassman</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Palmaira</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Covington</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ku</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Varghese</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>O'Reilly</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.</article-title>
            <source>BMC Cancer</source>
            <year>2018</year>
            <month>Jun</month>
            <day>27</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>693</fpage>
            <pub-id pub-id-type="pmid">29945562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershenson</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Irinotecan in epithelial ovarian cancer.</article-title>
            <source>Oncology (Williston Park)</source>
            <year>2002</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5 Suppl 5</issue>
            <fpage>29</fpage>
            <page-range>29-31</page-range>
            <pub-id pub-id-type="pmid">12109803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishiwaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Negoro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sugiura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fukuoka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saijo</surname>
                <given-names>N</given-names>
              </name>
              <collab>Japan Clinical Oncology Group</collab>
            </person-group>
            <article-title>Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Jan</month>
            <day>10</day>
            <volume>346</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-91</page-range>
            <pub-id pub-id-type="pmid">11784874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rivory</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of irinotecan.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>777</fpage>
            <page-range>777-803</page-range>
            <pub-id pub-id-type="pmid">14988754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abang</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>The clinical pharmacology of topoisomerase I inhibitors.</article-title>
            <source>Semin Hematol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>3 Suppl 4</issue>
            <fpage>13</fpage>
            <page-range>13-21</page-range>
            <pub-id pub-id-type="pmid">9779877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoskins</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Irinotecan pharmacogenomics.</article-title>
            <source>Pharmacogenomics</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>1003</fpage>
            <page-range>1003-10</page-range>
            <pub-id pub-id-type="pmid">20602618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glimelius</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Benefit-risk assessment of irinotecan in advanced colorectal cancer.</article-title>
            <source>Drug Saf</source>
            <year>2005</year>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>417</fpage>
            <page-range>417-33</page-range>
            <pub-id pub-id-type="pmid">15853443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Different schedules of irinotecan administration: A meta-analysis.</article-title>
            <source>Mol Clin Oncol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>361</fpage>
            <page-range>361-366</page-range>
            <pub-id pub-id-type="pmid">27446580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuchs</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Irinotecan in the treatment of colorectal cancer.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>7</issue>
            <fpage>491</fpage>
            <page-range>491-503</page-range>
            <pub-id pub-id-type="pmid">16959432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawazoe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shinozaki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suenaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsusaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mizunuma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hatake</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens.</article-title>
            <source>Oncol Lett</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>247</fpage>
            <page-range>247-251</page-range>
            <pub-id pub-id-type="pmid">22866072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60879.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raymond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boige</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Faivre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sanderink</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Rixe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vernillet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jacques</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gatineau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ducreux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Armand</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.</article-title>
            <source>J Clin Oncol</source>
            <year>2002</year>
            <month>Nov</month>
            <day>01</day>
            <volume>20</volume>
            <issue>21</issue>
            <fpage>4303</fpage>
            <page-range>4303-12</page-range>
            <pub-id pub-id-type="pmid">12409328</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
